Avicanna.png
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
20 oct. 2022 07h30 HE | Avicanna Inc.
TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicenna Academy
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
18 oct. 2022 07h30 HE | Avicanna Inc.
The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain...
Avicanna.png
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto
15 sept. 2022 09h09 HE | Avicanna Inc.
Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and...
Avicanna.png
Avicanna Announces Results of Annual General and Special Meeting
01 sept. 2022 07h30 HE | Avicanna Inc.
TORONTO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna.png
Avicanna Announces Closing of Strategic Private Placement
17 août 2022 17h00 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna.png
Avicanna Reports Q2 2022 Financial Statement
15 août 2022 17h00 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
220720 AVCN NR Image
Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals
20 juil. 2022 07h30 HE | Avicanna Inc.
Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform TORONTO, July 20, 2022 (GLOBE...
Avicanna.png
Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders
11 juil. 2022 17h15 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
220707 AVCN NR Image
Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union
07 juil. 2022 07h30 HE | Avicanna Inc.
The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio Initial portfolio launch is planned for Germany, Austria, and...
Avicanna.png
Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa
24 juin 2022 07h30 HE | Avicanna Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...